[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527009":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":21,"locations":31,"responsibleParty":55,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":10,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":77,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Shanghai Ming Ju Biotechnology Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Relmacabtagene Autoleucel",null,"Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.",[13],"Biological: Relmacabtagene Autoleucel",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells",[9],[20],"JWCAR029",[22,27],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"Yuqing Song, PhD","CONTACT","+86 010-88121122","songyuqin622@163.com",{"name":28,"role":24,"phone":29,"phoneExt":10,"email":30},"Medical JWCAR029","+86 21 50464201","JWCAR029Medical@jwtherapeutics.com",[32,47],{"facility":33,"status":10,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Beijing Cancer Hospital","Beijing","Beijing Municipality","100010","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":23,"role":24,"phone":10,"phoneExt":10,"email":10},{"facility":48,"status":10,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":51,"contacts":52},"Peking University International Hospital",{"type":40,"coordinates":50},[42,43],{"lat":43,"lon":42},[53],{"name":54,"role":24,"phone":10,"phoneExt":10,"email":10},"Xinjian Liu",{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100527009","relmacabtagene-autoleucel-in-hematologic-malignancies-100527009",false,"NCT06142188","Relmacabtagene Autoleucel in Hematologic Malignancies","A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel","Inclusion Criteria:\n\n1. Signed informed consent\n2. Patients who have been treated with Relma-cel, including those who have received off-label products;\n3. If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.\n\nExclusion Criteria:\n\n1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.","ALL","18 Years",{"count":67,"type":68},150,"ESTIMATED","OBSERVATIONAL","To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world",[72,73,74],"Lymphoma, B-Cell","Large B-cell Lymphoma","Follicular Lymphoma",[9,76],"Chimeric antigen receptor T cells","NOT_YET_RECRUITING","2023-11-15",{"date":80,"type":81},"2023-11-21","ACTUAL",{"date":83,"type":68},"2023-12-28",{"date":85,"type":68},"2038-12-31",{"name":5,"class":6},2]